Aldeyra Therapeutics, Inc. · NASDAQ:ALDX
Aldeyra Therapeutics — IPO Roadshow (April 2014)
26 slides from Aldeyra Therapeutics's IPO roadshow presentation, Apr 29, 2014
Slide 1: A Pharmaceutical Platform Focused on Trapping Aldehydes
Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333-193204 April 29, 2014 A Pharmaceutical Platform Focused on Trapping Aldehydes
Slide 2: Forward-Looking Statements
Forward-Looking This “objective,” intended you sufficiency which labeling ability expectations product Forward-looking performances by in Although our result Registration financial developments You 2inherent the law, actual should should presentation of, future. we towe candidates; for in to conditi
Slide 3: Free Writing Prospectus legend
Freebecome This We yet information website Alternatively, 10019, have Writing presentation telephone: atfiled http://www.sec.gov. effective. about Prospectus we a registration or highlights 212-813-1010, usany and Before underwriter Statement thestatement basic offering. you invest, e-mail: informat
Slide 4: Offering Summary
Offering Issuer Clinical Use 4Sole of Book-Runner Aldeyra Proceeds development Summary Therapeutics, and Aegis other of NS2, Capital general Inc. working Corp. Exchange/Ticker corporate capital, purposes NASDAQ Capital Market / ALDX Shares Offered 1,200,000 (100% primary) Over-Allotment 15% or 180,0
Slide 5: Management and Board of Directors
Management business Domain Xanthus/Antisoma), Pharmaceuticals –Scott Oxigene, 5Todd overYoung Genetics Brady, Brady 15Associates, 25and Repligen years Institute, ––M.D., clinical and CEO Chief of(acquired Directors pharmaceutical Ph.D. Aldeyra Phenome Genzyme, Aderis Operating development –by Presid
Slide 6: Investment Highlights
Investment Unique, Rare Modest $5M Initiate Lead Large Markets Strong Extend Marquee 6Johnson and for compound Markets Patent one to Funding Innovative for & currently Investors mass-market late Johnson Highlights Phase orphan Portfolio 2020s with in Required II/III planned Validate two indications
Slide 7: Aldehydes Are Toxic
Aldehydes Toxic Modify Dehydrogenases Modification High 7Cytokine levels mediators cellular Release Are are eliminate Mediators implicated constituents, of attempt NF-KB numerous free toActivation of inMetabolism aldehydes Disease Free autoimmune, diseases Aldehydes inflammatory, lead to indigestibl
Slide 8: Aldeyra's Novel Therapeutic Approach: Aldehyde Traps
Aldehyde Adduct Cellular 8Aldeyra’s ••Trapped Drug Traps: •lead Aldeyra’s aldehyde and Aaldehydes Novel aldehydes compounds trap, Therapeutic are NS2, are Transport rapidly Disposal appears Approach trap transported metabolized to Binding have minimal to free within thealdehydes pharmacology; lysoso
Slide 9: Trapping Aldehydes Generates Broad Anti-Inflammatory Response
Trapping Mice endotoxin 0% Levels hours Cytokine *** In an-80% endotoxin treated after -20% Aldehydes ** Reduction exposure; endotoxin Vehicle with model NS2 Generates TNF-a in ** exposure of or -60% -100% cytokine vehicle IL-1b **a-40% ** vs. Broad 30 IL-5 p<0.01 generation minutes IL-17 Anti-Infla
Slide 10: NS2 Decreases Inflammation in Animal Models
NS2 0)150 Vehicle Murine Single 10 )0* 150 p<0.05 Decreases dose Model NS2of (mm Vehicle NS2 of Dermal (mm Contact has NS2 ** Inflammation early Dermatitis p<0.01 and potent * Thickness (PMA) in Animal anti-inflammatory Murine 100Models **Model Thickness effect of Allergic 100 thatEar reduces Dermat
Slide 11: NS2 Speeds Healing and Reduces Scarring in Animal Models
Hamster 3V Severe 026(percent NS Day NS2 11ehicle 21 None 36 Speeds Minimal speeds Moderate change) cheek lesion Healing pouch p=0.1 healing and radiation-induced Score Reduces and 2reduces Score Scarring Marked scarring oralofmucositis Lesions mucositis in a model in Animal p=0.01 of skinModels Fib
Slide 12: NS2 Protects Skin and Eye Cells
Aldehyde- p<0.01 Normal NS2 12 Protects prevents SLSAldehyde SLS aaldehyde-mediated KeyMutants Lipid Damaged Relevant + Human Aldehyde- damage toSkin SkinCells of Lipid and lipid Eye Cells Damaged that Disease Mutants is critical Control inNS2 Cell to dermal Lipid Systems NS2+Aldehyde moisture barri
Slide 13: NS2 Reduces Aldehyde Levels in Human Tissue
NS2 Malondialdehyde Human 25 Levels Aldehyde Normal Potential (Including 13 )MTraps 10 20 Skin Tissue toLevels Sjögren-Larsson Aldehydes reduce Tissue Dry (Malondialdehyde concentration aldehyde-mediated Tissue Human Generated Dry Syndrome Ocular Tissue inbyhuman Tissue Dry mM) +damage and NS2 Condi
Slide 14: Summary of Efficacy: Multiple Mechanisms of Action
Decreased NS2 Anti-inflammatory Lesion The 14 same Summary Healing biological Aldehyde of Anti-fibrotic Efficacy: Load mechanisms Lipid Multiple Protection mayMechanisms apply to many of Action rare and prevalent diseases.
Slide 15: Positive Phase I Results: NS2 Eye Drop
-oPositive 15 Single Seven Two 48 healthy Double treatment day day NS2 masked 0.25% 0.25% volunteers Eyestages and Drop & & 0.5% placebo 0.5% for Phase two qid bidIcontrolled drug oResults &Eye qidconcentrations: drops were well tolerated in all treatment groups o No plasma exposure detected by LC-M
Slide 16: Ocular Aldehydes: Rosacea and Uveitis
Rosacea Uveitis Ocular Acute Pain, May Estimated 10M Aldehydes 16 exceed patients Burning/itching, Anterior anterior are 25,000 patients/year Ocular inflammatory Uveitis Uveitis: USocular photophobia, and A Rare Ocular mediators inflammation Inflammatory Rosacea eyelid of ocular swelling, inflammati
Slide 17: Anticipated Clinical Trial Designs
Anticipated Acute Uveitis Formulation Treatment Endpoints 17 Anterior Ocular Cell Time Clinical EyeRosacea Counts, 8Drop weeks Trial Eye Symptoms (1) 12 Designs Drop weeksControl for Ocular Ocular Active Signs, Disease 1:1 Symptoms Placebo 1:1 Total Patients 40-45 Patients 40 Patients
Slide 18: Sjögren-Larsson Syndrome: A Rare Disease
Sjögren-Larsson Rare Symptoms Diagnosed 50s (1) 18 Extrapolating Europe diseaseat include (1) caused birth, would Syndrome from by butbe mutation aEstimated Swedish analogous (SLS): in estimate, no Fatty Atoapproved Rare ansevere enzyme Disease it istherapy skin generally replacement with thickening
Slide 19: Unmet Medical Need for Our Clinical Indications
Unmet We There Therapies 21 believe isMedical nofor market FDA-approved discoid Need demand lupus for Our therapy is andsubstantial Clinical acute foranterior Indications Sjögren-Larsson Ocular for a uveitis Rosacea novel therapy arewith Syndrome associated Meibomian that is safe withand Gland signi
Slide 20: Orphan Market: Attractive Pricing
Orphan Twice Payer >$200,000 *Total 22NS2US research per has Topical SLS day not permarket: received surface year Estimated Drug: Pricing higher Attractive area ~$200M orphan forconfirms pricing treatment Cutaneous designation Pricing, for similar treated aLymphoma topical Large or SLS Market 25% th
Slide 21: Intellectual Property Portfolio
Intellectual Formulation Method NS2 *Pending 23 to 2033 Uses inProperty Brazil, Topical in forUS, aldehyde India assuming dosing Portfolio: traps Hatch-Composition Composition in diseases of Matter Waxman into the extension; 2030s Issued or allowed worldwide*
Slide 22: Rare Disease Valuation Comparables
Diseases Company Aldeyra (midpoint Bluebird Sarepta Intercept Rare (1) 24 Anticipated $77M Disease disease-focused Therapeutics Therapeutics in Bio Pharmaceuticals Stage post-money) (BLUE) Company by Phase end(SRPT) biotechnology (ALDX) Phase II ofValuation or 2014, (ICPT) III IIPhase Valuation 2Pha
Slide 23: Rare Disease Valuation Comparables
Diseases Company Aldeyra (midpoint Bluebird Sarepta Intercept Rare (1) 23 Anticipated $66M Disease disease-focused Therapeutics Therapeutics in Bio Pharmaceuticals Stage post-money) (BLUE) Company by Phase end(SRPT) biotechnology (ALDX) Phase II ofValuation or 2014, (ICPT) III IIPhase Valuation 2Pha
Slide 24: Pre-IPO Capitalization Structure
Pre-IPO Capitalization Common (1) (3) 24 Includes Common Capital Stock Preferred Stock Shares (1) Structure 3,970,164 to Outstanding be Stock issued to85% be upon converted %Stock Outstanding net exercise Options to Common of (2)outstanding 609,842 Stock13% atwarrants IPO Warrants (2) Does at IPO (3
Slide 25: Use of Proceeds and Anticipated News Flow
Use –Research Working Data 25Orphan Phase of from Proceeds II/III III capital and for designations, for allNS2 for trials Development: discoid acute ocular and and Sjögren-Larsson oral expected anterior other rosacea News lupus administration INDgeneral Flow uveitis $10M filings, in 2015 Syndrome co
Slide 26: Investment Highlights
Investment Rare, Orphan Modest $5M Initiate Lead Large Markets Strong Extend Marquee Johnson 26 for compound Innovative Markets Patent four to and Funding for & currently Investors late Johnson Highlights mass-market orphan Phase Portfolio 2020s with in Required Platform planned II Validate 4indicat